Skip to Content
Merck
  • Transient Mitomycin C-treatment of human corneal epithelial cells and fibroblasts alters cell migration, cytokine secretion, and matrix accumulation.

Transient Mitomycin C-treatment of human corneal epithelial cells and fibroblasts alters cell migration, cytokine secretion, and matrix accumulation.

Scientific reports (2019-09-27)
Sonali Pal-Ghosh, Gauri Tadvalkar, Verna Rose Lieberman, Xiaoqing Guo, James D Zieske, Audrey Hutcheon, Mary Ann Stepp
ABSTRACT

A single application of Mitomycin C (MMC) is used clinically in ophthalmology to reduce scarring and enhance wound resolution after surgery. Here we show in vitro that a 3-hour MMC treatment of primary and telomerase immortalized human corneal limbal epithelial (HCLE) cells impacts their migration and adhesion. Transient MMC treatment induces HCLE expression of senescence associated secretory factors, cytokine secretion, and deposition of laminin 332 for several days. Transient MMC treatment also reduces migration and deposition of transforming growth factor-β1 (TGFβ1)-stimulated collagen by corneal fibroblasts. Using conditioned media from control and MMC treated cells, we demonstrate that factors secreted by MMC-treated corneal epithelial cells attenuate collagen deposition by HCFs whereas those secreted by MMC-treated HCFs do not. These studies are the first to probe the roles played by corneal epithelial cells in reducing collagen deposition by corneal fibroblasts in response to MMC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Tenascin antibody produced in rat, clone MTn-12, ascites fluid
Sigma-Aldrich
Magnesium methyl carbonate solution, 2.0 M in DMF
Sigma-Aldrich
Anti-Collagen Type I Rabbit pAb, liquid, Calbiochem®